3 Top Pharma Stocks to Buy This Month

Stock Markets1 hour ago (Jun 08, 2021 08:31PM ET)

(C) Reuters. 3 Top Pharma Stocks to Buy This Month

Performance in pharmaceutical stocks has taken a step back after showing strong momentum through February. David Cohne believes this is temporary and is suggesting investors consider top pharma stocks such as Bristol-Myers Squibb Company (NYSE:BMY), Johnson & Johnson (JNJ), and Novo Nordisk A/S (NYSE:NVO).In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19. As represented by the SPDR S&P Pharmaceuticals ETF (XPH), the pharmaceutical industry gained 75% from March 23, 2020, to February 8, 2021. It has since leveled off a bit as the ETF is down 7% since then. But this provides us a buying opportunity to pick up some shares on the dip.

Much like technology companies, healthcare companies, and pharmaceutical companies, in particular, represent the future, as an aging boomer population will start requiring more medications and healthcare needs. A large percentage of the population is already heavily medicated, so imagine what it will be like in twenty to thirty years. That’s why adding pharmaceutical companies to your portfolio now isn’t a bad idea.

The key is finding companies with solid fundamentals and consistent growth, which our proprietary POWR Ratings system can help you with. So, I ran a screen for three top pharmaceutical companies in our database that also had notable growth drivers expected to drive their share prices up. This is why I am highlighting Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), and Novo Nordisk A/S (NVO) below.

Continue reading on StockNews

3 Top Pharma Stocks to Buy This Month

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Stories

Discover

The Nubank EC-1

Brazil is a country riven with economic contradictions. It has one of the largest...

How contrarian hires and a pitch deck started Nubank’s...

For most startups, the hardest early challenge is identifying a market and a product...

One woman’s drive to make a neobank as magical...

As we mentioned in part 1 of this EC-1, David Velez had two key...

How Nubank’s CX strategy made it one of the...

As we saw in parts 1 and 2 of this EC-1, by mid-2013, Nubank...

Which Nubank will own the financial revolution?

Nubank’s first office, on California Street in the Brooklin neighborhood of São Paulo, makes...

Beats Studio Buds offer a compact design, noise-canceling and...

When they were released in 2019, Powerbeats Pro were standouts. Two-plus years later, they...

Popular Categories